When coming to the data of pretreatment patients (Fig. 9G–L), MTHFR could act as a potential biomarker for pembrolizumab to melanoma of anti-PD-1 therapy (AUC = 0.704, P < 0.0001). This evidence concerns the gene PDCD1 and melanoma.